‘In this cohort of patients hospitalised for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomised, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)’
In this short conclusion in its introduction, the paper published by the New England Journal of Medicine, mentions specifically who funded it.
Read here (New England Journal of Medicine, April 10, 2020)
